BACKGROUND: The hyper-IgD and periodic fever syndrome (HIDS) is characterized by recurrent attacks of fever, abdominal distress, and arthralgia and is caused by mevalonate kinase mutations. OBJECTIVE: To ascertain the role of mevalonate kinase and the usefulness of molecular diagnosis in HIDS. DESIGN: Cross-sectional study. SETTING: The international Nijmegen HIDS registry. PATIENTS: 54 patients from 41 families who met the clinical criteria for HIDS. MEASUREMENTS: Clinical symptoms and signs, immunoglobulin concentration, leukocyte count, erythrocyte sedimentation rate, mutation analysis, and mevalonate kinase enzyme activity assay. RESULTS: There were two groups of patients: 41 patients with mevalonate kinase mutations (classic-type HIDS) and 13 patients without mutations (variant-type HIDS). Patients with classic-type HIDS had a lower mevalonate kinase enzyme activity, a higher IgD level, and more additional symptoms with attacks. The IgD level did not correlate with disease severity, mevalonate kinase enzyme activity, or genotype. CONCLUSION: Genetic heterogeneity exists among patients with a clinical diagnosis of HIDS.
BACKGROUND: The hyper-IgD and periodic fever syndrome (HIDS) is characterized by recurrent attacks of fever, abdominal distress, and arthralgia and is caused by mevalonate kinase mutations. OBJECTIVE: To ascertain the role of mevalonate kinase and the usefulness of molecular diagnosis in HIDS. DESIGN: Cross-sectional study. SETTING: The international Nijmegen HIDS registry. PATIENTS: 54 patients from 41 families who met the clinical criteria for HIDS. MEASUREMENTS: Clinical symptoms and signs, immunoglobulin concentration, leukocyte count, erythrocyte sedimentation rate, mutation analysis, and mevalonate kinase enzyme activity assay. RESULTS: There were two groups of patients: 41 patients with mevalonate kinase mutations (classic-type HIDS) and 13 patients without mutations (variant-type HIDS). Patients with classic-type HIDS had a lower mevalonate kinase enzyme activity, a higher IgD level, and more additional symptoms with attacks. The IgD level did not correlate with disease severity, mevalonate kinase enzyme activity, or genotype. CONCLUSION: Genetic heterogeneity exists among patients with a clinical diagnosis of HIDS.
Authors: John Gately Luz; Christian A Hassig; Catherine Pickle; Adam Godzik; Barbara J Meyer; Ian A Wilson Journal: Genes Dev Date: 2003-04-02 Impact factor: 11.361
Authors: E Lainka; U Neudorf; P Lohse; C Timmann; M Bielak; S Stojanov; K Huss; R von Kries; T Niehues Journal: Rheumatol Int Date: 2011-10-30 Impact factor: 2.631
Authors: Sven Armbrust; Joost P H Drenth; Carmen Schröder; Ester Domning; Ernestine Poeschl; Siegfried K W Wiersbitzky Journal: Eur J Pediatr Date: 2005-03-16 Impact factor: 3.183
Authors: I Jéru; P Duquesnoy; T Fernandes-Alnemri; E Cochet; J W Yu; M Lackmy-Port-Lis; E Grimprel; J Landman-Parker; V Hentgen; S Marlin; K McElreavey; T Sarkisian; G Grateau; E S Alnemri; S Amselem Journal: Proc Natl Acad Sci U S A Date: 2008-01-29 Impact factor: 11.205